These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Dynamics of anti-HEV ORF2, ORF3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance].
    Author: Ruan B, Zhuang H, Ma Y.
    Journal: Zhonghua Yi Xue Za Zhi; 1998 Jul; 78(7):498-500. PubMed ID: 10923456.
    Abstract:
    OBJECTIVE: To study the dynamics of anti-HEV ORF2, ORF3, IgM and IgG in serial sera of patients with hepatitis E. METHODS: Anti-HEV was detected in serial sera of 52 patients, by an enzyme-linked immunosorbent assay (EIA) based on two synthetic peptides separated or combined from open reading frame (ORF) 2 and 3 of HEV genome. RESULTS: Both anti-ORF2 and anti-ORF3 in serum were at the highest levels in early acute phase of the disease, and declined gradually with the course, especially anti-ORF3. The sensitivity of the EIA using both ORF2 and ORF3 peptides was higher than that of either alone. The positive rates of anti-HEV IgM and anti-HEV IgG were separately 71.1% (32/45) and 97.8% (44/45) within 15 days after onset, then decreased more dramatically in IgM than in IgG with the course. CONCLUSION: Both ORF2 and ORF3 proteins should be used for the development of anti-HEV EIA kit. It seems to be more specific in anti-HEV IgM and more sensitive in anti-HEV IgG as a diagnostic marker of hepatitis E.
    [Abstract] [Full Text] [Related] [New Search]